Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 24, 2026
- Amount
- $2,500,000
- Closes
- Feb 18, 2027 (in 105 days)
Similar opportunities open now
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 29, 2027 (in 85 days)
- Immune Tolerance Network (UM1 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 29, 2027 (in 85 days)
- Engineering Biological and Biomedical SystemsOpenNational Science FoundationNo deadline listed
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026
- Systems and Synthetic BiologyOpenNational Science FoundationNo deadline listed
Classification and identifiers
- Solicitation number
- RFA-AI-28-014
- Assistance listing (CFDA)
- 93.543
Amount
$2,500,000
Who can apply
Local government agencies can apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting multidisciplinary, consortium-based research using precision systems biology approaches to uncover links among chronic illnesses, infectious diseases and microbiomes. There is an urgent scientific and clinical need to understand the pathways by which infections lead to chronic lifelong health issues or alternatively, how long-term illnesses might predispose or exacerbate acute infections. The objective is to harness cutting-edge technologies along with longitudinal patient cohorts and biobank data for comprehensive analysis of genetic, environmental, and lifestyle factors leading to advances in prevention and treatment strategies for both chronic and infectious diseases. The cutting...